Proximagen granted H. Lundbeck the option to license three of Proximagen's programs, including epilepsy, pain and inflammation, for a 9% equity stake

Proximagen Group plc

U.K. / Small-Cap Biopharma (<$1 billion)

$121.4m on 09/30/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

H. Lundbeck A/S

Denmark / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced